Mexico’s new president promises to overhaul the country’s healthcare system to make it more like Canada’s. In the meantime, the country faces an HIV medication shortage that puts patients at risk. Researcher warns that pollution, among other causes, has led to respiratory diseases in 2 percent of the population. Finally, the Ministry of Health denied that the country is facing an influenza epidemic.
In international news, the pharmaceutical sector starts the new year with strong investments with Bristol-Myers Squibb acquisition of Celgene for US$74 billion and Eli Lilly’s US$8 billion for Loxo Oncology. In other news, Novartis’ sickle cell treatment gets FDA’s Breakthrough Therapy designation.
Now, about last week’s highlights:
President Andrés Manuel López Obrador vowed to improve Mexico’s healthcare to resemble that of Canada, the UK or Denmark within the next two years.
Medication shortage hurts about 60,000 HIV patients mainly in Quintana Roo, Campeche, Chihuahua and Coahuila.
Researcher from UNAM’s Institute of Neurobiology said 2 percent of the population have respiratory diseases including asthma and bronchitis.
Ministry of Health shuts down rumors of an influenza epidemic in the country.
Eli Lilly expands oncology portfolio through the acquisition of Loxo Oncology for US$8 billion.
Bristol-Myers Squibb acquires Celgene for US$74 billion in cash and stock transaction.
Novartis’ crizanlizumab for sickle cell disease patients gets FDA’s Breakthrough Therapy designation. This disease causes painful events with potential severe acute and chronic complications.